Latest News of FULC
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...
By Yahoo! Finance |
4 days ago
Fulcrum Therapeutics plans to keep its new assets wholly-owned for now, focusing on inherited aplastic anemias. The company received positive feedback from the FDA for healthy volunteer studies on poc...
Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
By Yahoo! Finance |
1 month ago
Cash runway guidance indicates funding to cover operations until 2027. Discussions covered FDA validation of metrics, trial delays, and value proposition for losmapimod. The company is confident in ac...
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
By Yahoo! Finance |
2 months ago
BofA Securities upgraded Fulcrum Therapeutics ahead of phase 3 losmapimod readout for FSHD, a rare genetic muscle disease. The company's new study using the "reachable workspace" endpoint has sparked ...
-
Fulcrum Therapeutics (NASDAQ:FULC) delivers shareholders stellar 110% return over 1 year, surging 27% in the last week alone
By Yahoo! Finance | 4 months agoInvesting in stocks carries risks, but choosing the right stock can lead to significant returns. Fulcrum Therapeutics' stock price has surged 110% in a year, despite a 38% revenue decrease. Investors ...